| Literature DB >> 34103096 |
Jérémy T Campillo1, Naomi P Awaca-Uvon2, Jean-Paul Tambwe2, Godefroy Kuyangisa-Simuna2, Johnny Vlaminck3, Gary J Weil4, Michel Boussinesq1, Cédric B Chesnais1, Sébastien D S Pion5.
Abstract
BACKGROUND: The impact of semiannual mass drug administration (MDA) with albendazole (ALB; 400 mg) alone on lymphatic filariasis (LF) and soil-transmitted helminth (STH) infections was assessed during two trials conducted from 2012 to 2018 in the Republic of Congo and the Democratic Republic of Congo. The collected data were analyzed to evaluate the effect of compliance with ALB treatment on STH infections.Entities:
Keywords: Albendazole; Mass drug administration; Parametric survival analysis; Soil-transmitted helminths; Treatment adherence
Year: 2021 PMID: 34103096 PMCID: PMC8186172 DOI: 10.1186/s13071-021-04814-2
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Sustained clearance rates for hookworm, Ascaris and Trichuris infections
| Variables | Categories | Hookworm (202 individuals) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PY | No. of events | Ratea | 95% CI | PY | No. of events | Ratea | 95% CI | PY | No. of events | Ratea | 95% CI | |||||
| All participants | 701 | 135 | 19.2 | 16.2–22.8 | 681 | 172 | 25.2 | 21.7–29.3 | 1019 | 86 | 8.4 | 6.8–10.4 | ||||
| Sex | Male | 390 | 69 | 17.7 | 14.0–22.4 | 0.023 | 299 | 63 | 21.1 | 16.5–27.0 | 0.017 | 420 | 36 | 8.6 | 6.2–11.9 | 0.919 |
| Female | 311 | 66 | 21.2 | 16.7–27.9 | 382 | 109 | 28.5 | 23.7–34.4 | 599 | 50 | 8.3 | 6.3–11.0 | ||||
| Age | 5–8 Years | 245 | 30 | 12.2 | 8.6–17.5 | 0.009 | 153 | 20 | 13.1 | 8.4–20.3 | 0.001 | 201 | 7 | 3.5 | 1.7–7.3 | < 0.001 |
| 8–12 Years | 166 | 39 | 23.5 | 17.2–32.2 | 189 | 46 | 24.3 | 18.2–32.5 | 222 | 9 | 4.0 | 2.1–7.8 | ||||
| 13–30 Years | 135 | 24 | 17.8 | 11.9–26.5 | 117 | 32 | 27.3 | 19.3–38.7 | 209 | 16 | 7.6 | 4.7–12.5 | ||||
| ≥ 31 Years and more | 155 | 42 | 27.1 | 20.0–36.6 | 222 | 74 | 33.3 | 26.5–41.9 | 387 | 54 | 13.9 | 10.7–18.2 | ||||
| Initial infection intensityb | Light | 575 | 131 | 20.0 | 16.8–23.7 | 0.059 | 269 | 77 | 28.6 | 22.9–35.8 | 0.022 | 634 | 74 | 11.7 | 9.3–14.7 | < 0.001 |
| Moderate | 29 | 4 | 13.8 | 5.2–36.5 | 374 | 87 | 23.3 | 18.8–28.7 | 369 | 11 | 3.0 | 1.6–5.4 | ||||
| Heavy | 16 | 0 | 0 | N/A | 38 | 8 | 21.0 | 10.5–42.1 | 16 | 1 | 6.2 | 0.9–44.4 | ||||
| Village | Misay | 323 | 61 | 18.9 | 14.7–24.3 | 0.001 | 44 | 8 | 18.2 | 9.1–36.3 | 0.247 | 3 | 1 | N/A | N/A | |
| Mbunkimi | 336 | 56 | 16.7 | 12.8–21.6 | 41 | 13 | 31.7 | 18.4–54.6 | 20 | 4 | N/A | N/A | ||||
| Seke Pembe | 42 | 18 | 42.8 | 27.0–68.0 | 596 | 151 | 25.3 | 21.6–29.7 | 994 | 80 | 8.0 | 6.5–10.0 | ||||
P is calculated from significance tests using the Mantel–Haenszel method based on stratified rate ratios
PY Person-years, CI confidence interval
aInfection status conversion rate (for 100 PY)
bAccording to World Health Organization (WHO) guidelines: for hookworm, 1–1999 (light), 2000–3999 (moderate), > 4000 eggs per gram of stool (EPG) (heavy); for Ascaris, 1–4999 (light), 5000–49,999 (moderate), > 49,999 EPG (heavy); for Trichuris, 1–999 (light), 1000–9999 (moderate), > 10,000 EPG (heavy)
Results of parametric survival models for sustained clearance of hookworm, Ascaris and Trichuris infections (with random effects)
| Variables | Categories | Hookworm | |||||
|---|---|---|---|---|---|---|---|
| TR/95% CIa | TR/95% CIa | TR/95% CIa | |||||
| Sex | Female | Ref. | Ref. | Ref. | |||
| Male | 1.10 (1.01, 1.19) | 0.020 | 1.11 (1.02, 1.21) | 0.013 | 0.99 (0.92, 1.06) | 0.807 | |
| Age | 5–8 Years | Ref. | Ref. | Ref. | |||
| 8–12 Years | 0.93 (0.83, 1.04) | 0.223 | 0.95 (0.86, 1.08) | 0.398 | 1.06 (0.91, 1.23) | 0.452 | |
| 13–30 Years | 0.87 (0.77, 0.98) | 0.019 | 0.86 (0.75, 1.00) | 0.046 | 0.96 (0.83, 1.10) | 0.557 | |
| More than 30 years | 0.79 (0.70, 0.88) | < 0.001 | 0.81 (0.71, 0.92) | 0.001 | 0.88 (0.77, 0.99) | 0.049 | |
| Initial infection intensityb | Light | Ref. | Ref. | Ref. | |||
| Moderate to heavy | 1.20 (0.98, 1.46) | 0.072 | 1.06 (0.97, 1.16) | 0.170 | 1.18 (1.07, 1.31) | < 0.001 | |
| Treatment | Zero dose per year | 1.16 (1.00, 1.35) | < 0.001 | 1.74 (1.28, 2.38) | < 0.001 | Not calculable | |
| One dose per year | Ref. | Ref. | Ref. | ||||
| Two doses per year | 0.91 (0.81, 1.02) | 0.112 | 0.87 (0.79, 0.95) | 0.004 | 0.84 (0.77, 0.91) | < 0.001 | |
| Random effects | Village | < 0.001 | Not included | Household | 0.002 | ||
| ICC | 18.0% | 12.2% | |||||
| Model | Distribution | Log normal | Log normal | Log logistic | |||
| AIC | 464.1 | 515.9 | 410.2 | ||||
| Log likelihood | − 222.0 | − 249.0 | − 196.1 | ||||
Ref. Reference, ICC intraclass correlation coefficient, AIC Akaike information criterion; for other abbreviations, see Table 1
aAdjusted time ratio (TR)/95% confidence intervals (CI). For example, for the Ascaris model, compared to a female (TR = 1), it took 11% (TR = 1.11) more time to achieve sustained clearance in a male
bAccording to WHO guidelines: for hookworm, 1–1999 (light), > 2000 EPG (moderate to heavy); for Ascaris, 1–4999 (light), > 5000 EPG (moderate to heavy); for Trichuris, 1–999 (light), > 1000 EPG (moderate to heavy)
Fig. 1a–c The influence of compliance with albendazole treatment on soil-transmitted helminth infection status in study participants with prior infections. a Hookworm, b Ascaris, c Trichuris
Results of parametric survival models for incident hookworm, Ascaris and Trichuris infections (with random effects)
| Variables | Categories | Hookworm | |||||
|---|---|---|---|---|---|---|---|
| TR/95% CI | TR/95% CI | TR/95% CI | |||||
| Sex | Female | Ref. | Ref. | Ref. | |||
| Male | 1.39 (1.11, 1.73) | 0.004 | 1.10 (0.94, 1.19) | 0.234 | 1.22 (1.031, 1.44) | 0.018 | |
| Age | 5–8 Years | Ref. | Ref. | Ref. | |||
| 8–12 Years | 1.12 (0.87, 1.45) | 0.361 | 1.07 (0.88, 1.32) | 0.489 | 0.88 (0.73, 1.05) | 0.156 | |
| 13–30 Years | 1.02 (0.72, 1.46) | 0.872 | 1.13 (0.87, 1.46) | 0.364 | 0.62 (0.46, 0.84) | 0.002 | |
| More than 30 years | 0.95 (0.70, 1.28) | 0.738 | 1.11 (0.87, 1.41) | 0.412 | 0.53 (0.40, 0.70) | < 0.001 | |
| Treatment | Zero doses per year | 0.79 (0.51, 1.22) | 0.290 | 0.62 (0.42, 0.91) | 0.001 | 0.78 (0.53, 1.13) | 0.190 |
| One dose per year | Ref. | Ref. | Ref. | ||||
| Two doses per year | 0.97 (0.70, 1.33) | 0.828 | 1.10 (0.80, 1.50) | 0.559 | 1.14 (0.85, 1.54) | 0.385 | |
| Random effects | Village | < 0.001 | Village | < 0.001 | Household | < 0.001 | |
| ICC | 31.4% | 45.7% | 42.9% | ||||
| Model | Distribution | Log logistic | Log normal | Log logistic | |||
| AIC | 505.5 | 626.5 | 718.4 | ||||
| Log likelihood | − 243.7 | − 304.2 | − 350.2 | ||||
| Key survival data | Number of subjects | 102 | 177 | 194 | |||
| PY | 420 | 727 | 772 | ||||
For abbreviations, see Tables 1 and 2
Mixed model results for the evolution of EPG intensity
| Variables | Categories | Hookworm | |||||
|---|---|---|---|---|---|---|---|
| Coeff./95% CIa | Coeff./95% CIa | Coeff./95% CIa | |||||
| Sex | Female | Ref. | Ref. | Ref. | |||
| Male | 65.8 (− 34.4, 166.0) | 0.199 | 1056.7 (− 1115.9, 3229.2) | 0.340 | 234.2 (− 139.1, 607.5) | 0.219 | |
| Age | 5–8 Years | Ref. | Ref. | Ref. | |||
| 8–12 Years | 32.6 (− 122.6, 187.8) | 0.681 | − 4540.2 (− 7576.5, − 1504.0) | 0.003 | 126.1 (− 439.3, 691.6) | 0.662 | |
| 13–30 Years | − 128.0 (− 274.1, 18.0) | 0.086 | − 6432.5( − 9910.3, − 2954.8) | 0.0001 | − 333.9 ( − 929.6, 261.7) | 0.272 | |
| More than 30 years | − 107.1 (− 251.4, 37.1) | 0.088 | − 8030.3 (− 11035, − 5024.5) | < 0.001 | − 498.6 (− 1179.8, − 162.3) | 0.010 | |
| Initial infection intensityb | Light | Ref. | Ref. | Ref. | |||
| Moderate | 1155.4 (929.3, 1383, 5) | < 0.001 | 8727.8 (6302.6, 11153) | < 0.001 | 1061.2 (653.1, 1469.4) | < 0.001 | |
| Heavy | 3171.6 (2875.8, 3467.3) | < 0.001 | 33, 843 (28637, 39050) | < 0.001 | 6886.7 (5518.5, 8254.9) | < 0.001 | |
| Timec | Continuous | − 58.2 (− 263.2, 146.6) | 0.577 | 1631.5 (− 4174.5, 7437.4) | 0.582 | − 91.9 (− 378.8, 195.0) | 0.530 |
| Annual treatment interaction with timec | Zero doses | Ref. | Ref. | Not calculable | |||
| One dose | − 81.2 (− 316.0, 153.6) | 0.498 | − 7076.1 (− 13,103, − 1048.9) | 0.021 | Ref. | ||
| Two doses | − 197.1 (− 402.6, 8.4) | 0.060 | − 6207.3 (− 12,196, − 218.5) | 0.042 | − 207.5 (− 603.2, 188.3) | 0.304 | |
| Study site | Bandundu | Ref. | Ref. | Ref. | |||
| Seke Pembe | − 196.9 (− 427.8, 34.0) | 0.095 | 2596.8 (− 1004.8, 6198.3) | 0.158 | 721.0 (− 410.1, 1852.1) | 0.212 | |
| Intercept at baseline | Zero doses | 387.4 (− 478.5, 1253.2) | 0.381 | − 7884 − 33,495, 17,725.7) | 0.546 | Not calculable | |
| One dose | 272.7 (− 636.0, 1181.4) | 0.556 | 22,598 (− 3365.0, 48,561) | 0.088 | − 199.5 (− 170.9, 1305.9) | 0.795 | |
| Two doses | 404.0 (− 439.6, 1247.7) | 0.348 | 22,888 (− 2750.4, 48,527) | 0.080 | 936.6 (− 192.0, 2065.1) | 0.104 | |
aAdjusted regression coefficient (Coeff.)/95% CI
bAccording to WHO guidelines: for hookworm, 1–1999 (light), 2000–3999 (moderate), > 4000 EPG (heavy); for Ascaris, 1–4999 (light), 5000–49,999 (moderate), > 49,999 EPG (heavy); for Trichuris, 1–999 (light), 1000–9999 (moderate), > 10,000 EPG (heavy)
cInterpretation of the interaction variable: for the hookworm model, all else being equal, each participant’s EPG decreased by 58.2 each year; and all else being equal, participants taking one dose and two doses per year, as compared to zero doses, showed a decrease in their EPG by 81.2 and 197.1 EPG per year, respectively